New pneumonia vaccine VAX-31 aims to boost protection in older adults
NCT ID NCT07425392
First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This study tests a new vaccine called VAX-31 in adults aged 50 and older who have already received a pneumonia vaccine. The goal is to see if VAX-31 is safe and triggers a strong immune response. About 752 participants will receive either VAX-31 or an active comparator vaccine, and researchers will monitor side effects and antibody levels.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PNEUMOCOCCAL VACCINES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
AMR
Kansas City, Missouri, 64114, United States
-
Alcanza (Charlottesville Medical Research)
Charlottesville, Virginia, 22911, United States
-
Avacare (CCT Research)
Phoenix, Arizona, 85044, United States
-
CenExel (RCA)
Hollywood, Florida, 33024, United States
-
Center of American Indian Health
Gallup, New Mexico, 87301, United States
-
Chase Medical Research
Waterbury, Connecticut, 06708, United States
-
Chinle Center for Indigenous Health
Chinle, Arizona, 86503, United States
-
DM Clinical Research
Sugar Land, Texas, 77478, United States
-
DM Clinical Research-Detroit
Southfield, Michigan, 48076, United States
-
DelRicht Clinical Research
Stockbridge, Georgia, 30281, United States
-
DelRicht Clinical Research
New Orleans, Louisiana, 70115, United States
-
DelRicht Research
Hendersonville, Tennessee, 37075, United States
-
DelRicht Research (Command Family Medicine)
Springfield, Missouri, 65807, United States
-
Eximia (Health Awareness)
Jupiter, Florida, 33458, United States
-
Eximia (Health Awareness)
Port Saint Lucie, Florida, 34952, United States
-
Flourish Research
San Antonio, Texas, 78229, United States
-
Headlands (Trial Management Associates)
Wilmington, North Carolina, 28403, United States
-
Health Research of Hampton Roads, Inc.
Newport News, Virginia, 23606, United States
-
Johnson County Clin-Trials, LLC
Lenexa, Kansas, 66219, United States
-
Precision Clinical Research
Sunrise, Florida, 33351, United States
-
Quality Clinical Research
Omaha, Nebraska, 68114, United States
-
REX Clinical Trials
Beaumont, Texas, 77701, United States
-
Rochester Clinical Research, Inc.
Rochester, New York, 14609, United States
-
Shiprock Center for Indigenous Health
Shiprock, New Mexico, 87420, United States
-
Tekton Research
Edmond, Oklahoma, 73013, United States
-
Tekton Research
Austin, Texas, 78745, United States
-
The Villages
The Villages, Florida, 32162, United States
-
Velocity (Meridian Clinical Research)
Rockville, Maryland, 20854, United States
-
Velocity Clinical Valparaiso
Valparaiso, Indiana, 46383, United States
-
Whiteriver Center for Indigenous Health
Whiteriver, Arizona, 85941, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New vaccine targets 26 pneumococcal strains in early trial
- New 25-Valent pneumonia vaccine shows promise in phase 2 trial
- New combo shot study: could VAX-31 plus flu vaccine be a Game-Changer for seniors?
- Can a pneumonia vaccine protect the most vulnerable children?
- New vaccine aims to outsmart pneumonia bacteria
- New baby vaccine aims to beat pneumonia: VAX-31 trial underway